Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
Editorial
. 2023 Jun 19;15(12):5232-5234.
doi: 10.18632/aging.204839. Epub 2023 Jun 19.

Advances in cancer therapy: clinical benefit of new cancer drugs

Daniel Tobias Michaeli  1   2 , Julia Caroline Michaeli  3 , Thomas Michaeli  1   2   4   5
Affiliations
Editorial

Advances in cancer therapy: clinical benefit of new cancer drugs

Daniel Tobias Michaeli et al. Aging (Albany NY). .
No abstract available

Keywords: cancer drug; clinical benefit; clinical trial; overall survival; progression-free survival.

PubMed Disclaimer

Figures

Figure 1
Figure 1
Clinical benefit of new cancer drug indications approved by the FDA from 2003 to 2021. Notes: The waterfall plots visualize the clinical benefit of new cancer drug indications approved by the FDA between 2003 and 2021. Each blue bar represents the benefit of a single drug indication that was measured in the pivotal randomized controlled trial supporting the FDA approval. The red line indicates the median survival benefit. Graph (A) show the OS benefit and graph (B) the PFS benefit. In graph a, the outlier of midostaurin for acute myeloid leukemia with an OS benefit of 49.1 months was excluded for visualization purposes. Abbreviations: FDA, US Food and Drug Administration; OS, overall survival; PFS, progression-free survival.
See this image and copyright information in PMC

Similar articles

See all similar articles

Cited by

See all "Cited by" articles

References

    1. Siegel RL, et al.. CA Cancer J Clin. 2023; 73:17–48. 10.3322/caac.21763 - DOI - PubMed
    1. Michaeli DT, Michaeli T. J Clin Oncol. 2022; 40:4095–106. 10.1200/JCO.22.00535 - DOI - PubMed
    1. Prasad VK. Illustrated Edition. Johns Hopkins University Press. 2020.
    1. Michaeli DT, et al.. Appl Health Econ Health Policy. 2022; 20:757–68. 10.1007/s40258-022-00737-w - DOI - PMC - PubMed
    1. Michaeli DT, et al.. Invest New Drugs. 2022; 40:798–809. 10.1007/s10637-022-01227-5 - DOI - PMC - PubMed

Publication types

MeSH terms

Substances